Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 17Differentiated Thyroid Cancer 2Colorectal Neoplasms 2Cholangiocarcinoma 2Stomach Neoplasms 1Solid Tumor 1Recurrence 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hepatocellular Carcinoma with PVTT 1Esophageal Neoplasms 1Digestive System Neoplasms 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1Advanced Solid Tumor 1

Interventions

donafenib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Biliary Malignant Tumors × donafenib × Clear all
NCT06685289 2025-01-28

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
70 enrolled
Gastrointestinal

Biliary Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡